Tags · Evidence
effect size
Magnitude, not just direction or significance.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis
214 topics · page 4 of 8
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…
|
2 | 1.9k | 5mo | |
|
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
|
2 | 45k | 5mo | |
|
What I would record differently if I started again — the long version
What I would record differently if I started again — the long version I have a specific reason for asking rather than idle curiosity, and the context is below. Maintenance rather than loss, which is the part…
|
+22 | 26 | 57k | 5mo |
|
Heterogeneity as information rather than as a nuisance
Posting this under the heading it deserves: Heterogeneity as information rather than as a nuisance Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
|
+88 | 95 | 1.2k | 6mo |
|
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med ,…
|
3 | 28k | 6mo | |
|
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…
|
2 | 39k | 6mo | |
|
Designing a personal experiment that could change your mind
Posting this under the heading it deserves: Designing a personal experiment that could change your mind Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before…
|
+2 | 6 | 695 | 6mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…
|
+7 | 11 | 281 | 6mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
+19 | 23 | 20k | 7mo |
|
How to read a phase 2 result without treating it as a phase 3 result
The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…
|
+36 | 40 | 35k | 7mo |
|
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024) and…
|
+10 | 14 | 11k | 7mo |
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |
|
Reading SURMOUNT-1 without the press release
Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not…
|
+103 | 121 | 7k | 7mo |
|
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it
On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…
|
+2 | 6 | 2.4k | 7mo |
|
Measurement error in home scales, with a worked standard deviation — a second dataset
Measurement error in home scales, with a worked standard deviation — a second dataset — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with SURPASS-2…
|
2 | 13k | 7mo | |
|
Comparing my trajectory with the trial curves, carefully
Posting this under the heading it deserves: Comparing my trajectory with the trial curves, carefully Everything below is what sits behind that. Maintenance rather than loss, which is the part of this that…
|
+86 | 92 | 54k | 7mo |
|
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
|
2 | 48k | 7mo | |
|
About the Statistics category
Effect sizes, intervals, multiplicity, and the difference between absent and undetected. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+4 | 8 | 2.3k | 7mo |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
|
+57 | 64 | 12k | 7mo |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…
|
+85 | 90 | 13k | 7mo |
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
|
+18 | 29 | 20k | 8mo |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…
|
+6 | 10 | 6.1k | 8mo |
|
What pooling buys you and what it destroys
The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…
|
+74 | 83 | 6.6k | 8mo |
|
A preprint whose numbers changed substantially at publication — what changed since
On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it…
|
+3 | 7 | 125 | 8mo |
|
Journal club: how we handle discontinuation in obesity trials — what changed since
Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…
|
+14 | 18 | 35k | 8mo |
|
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
+1 | 5 | 31k | 8mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
+4 | 8 | 14k | 8mo |
|
What a confidence interval means, from scratch — the long version
The question in the title: What a confidence interval means, from scratch — the long version I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet , 2023) cited…
|
+16 | 20 | 2.3k | 8mo |
|
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…
|
+89 | 101 | 32k | 8mo |
|
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove
Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+81 | 90 | 54k | 9mo |